Literature DB >> 6414691

High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.

H O Klein, P D Wickramanayake, C Coerper, E Christian, J Pohl, N Brock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6414691     DOI： 10.1016/s0305-7372(83)80025-5

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  12 in total

1.  Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.

Authors:  D P Berger; H H Fiebig; B R Winterhalter; E Wallbrecher; H Henss
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.

Authors:  Xin Xiao; Wei Wang; Zhen Wang
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

3.  Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.

Authors:  J C Cervellino; C E Araujo; C Pirisi; O Sanchez; M Brosto; R Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.

Authors:  G Sangster; W N Patton; R I Harris; R J Grieve; M J Leyland
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.

Authors:  H Jürgens; U Exner; J Kühl; J Ritter; J Treuner; P Weinel; K Winkler; U Göbel
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Ifosfamide combination chemotherapy in advanced breast cancer.

Authors:  H Schmid; M Kaufmann; E M Grischke; G Bastert
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

8.  Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.

Authors:  T M Loeffler; F W Weber; T U Hausamen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.

Authors:  N Brock
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

10.  Ifosfamide treatment as a 10-day continuous intravenous infusion.

Authors:  H J Keizer; J Ouwerkerk; K Welvaart; C J van der Velde; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.